Huangming Y. Hong

No. 55, South Renmin Road
Chengdu, 610042, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 78 publications

Anti-TIM-3 antibody TQB2618 in combination with penpulimab in relapsed or refractory classic Hodgkin lymphoma previously treated with PD-1/PD-L1 therapy: a multicenter, open-label, single-arm, phase Ib clinical trial.

Anti-TIM-3 antibody TQB2618 in combination with penpulimab in relapsed or refractory classic Hodgkin lymphoma previously treated with PD-1/PD-L1 therapy: a multicenter, open-label, single-arm, phase Ib clinical trial.

Journal: Journal for immunotherapy of cancer

Published: March 30, 2026

SHR-A2102, a nectin-4 directed antibody-drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial.

SHR-A2102, a nectin-4 directed antibody-drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial.

Journal: The Lancet. Oncology

Published: January 13, 2026

Advanced Classical Hodgkin Lymphoma Management in East and Southeast Asia: Real-World Challenges and Aspirations of the Asian Lymphoma Study Group.

Advanced Classical Hodgkin Lymphoma Management in East and Southeast Asia: Real-World Challenges and Aspirations of the Asian Lymphoma Study Group.

Journal: JCO global oncology

Published: October 29, 2025

An inflammation-integrated prognostic nomogram for advanced-stage extranodal NK/T-cell lymphoma: a multicenter retrospective study.

An inflammation-integrated prognostic nomogram for advanced-stage extranodal NK/T-cell lymphoma: a multicenter retrospective study.

Journal: Annals of hematology

Published: October 22, 2025

Dynamic monitoring of circulating cell-free EBV-DNA for risk assessment in early-stage natural killer/T-cell lymphoma.

Dynamic monitoring of circulating cell-free EBV-DNA for risk assessment in early-stage natural killer/T-cell lymphoma.

Journal: Blood advances

Published: October 22, 2025

Peripheral T-Cell Lymphoma Management in East and Southeast Asia: Real-World Challenges and Aspirations of the Asian Lymphoma Study Group.

Peripheral T-Cell Lymphoma Management in East and Southeast Asia: Real-World Challenges and Aspirations of the Asian Lymphoma Study Group.

Journal: JCO global oncology

Published: October 22, 2025

Dynamic monitoring of circulating cell-free EBV-DNA for risk assessment in early-stage natural killer/T-cell lymphoma.

Dynamic monitoring of circulating cell-free EBV-DNA for risk assessment in early-stage natural killer/T-cell lymphoma.

Journal: Blood advances

Published: October 22, 2025

Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.

Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 02, 2025

6-month Progression-Free Survival (PFS6) as a prognostic factor in large B-cell lymphoma patients undergoing chimeric antigen receptor T-cell therapy: A real-world multicenter study.

6-month Progression-Free Survival (PFS6) as a prognostic factor in large B-cell lymphoma patients undergoing chimeric antigen receptor T-cell therapy: A real-world multicenter study.

Journal: Annals of hematology

Published: September 03, 2025

Targeting cancer-induced nerve injury reverses immunotherapy resistance.

Targeting cancer-induced nerve injury reverses immunotherapy resistance.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: September 02, 2025

A novel prognostic model based on CA stage for enhanced stratification and survival prediction in patients with Natural killer/T-cell lymphoma.

A novel prognostic model based on CA stage for enhanced stratification and survival prediction in patients with Natural killer/T-cell lymphoma.

Journal: Annals of hematology

Published: August 04, 2025

Mechanisms of chemoresistance in diffuse large B‑cell lymphoma and novel therapeutic strategies (Review).

Mechanisms of chemoresistance in diffuse large B‑cell lymphoma and novel therapeutic strategies (Review).

Journal: International journal of oncology

Published: July 08, 2025

Showing 1-12 of 78

Last Updated: 09/26/2026